SynthesisAsian Pacific journal of cancer prevention : APJCP2025
Survivin (BIRC5) Gene Polymorphism (rs9904341) Is Associated with Cancer Risk: A Meta-Analysis.
Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSurvivin (BIRC5) is an anti-apoptosis protein over expressed in most cancers and associated with poor clinical outcomes. We have provided an updated meta-analysis of -31G/C (rs9904341) gene polymorphism which is highly associated with cancer risk. METHODOLOGY: A comprehensive literature search in PubMed and Google Scholar databases was conducted. A total of 10472 cases and 12193 controls from 51 studies were included in this meta-analysis. This study was prospectively registered in PROSPERO, and sensitivity analysis, risk of bias analysis, and statistical analysis were performed. A pooled odds ratio (OR) with 95% confidence interval (CI) was calculated to assess the strength of the association. All analyses were achieved using RevMan 5.4 software and Excel 2013 version.
resultsThe overall meta-analysis indicates that survivin gene polymorphism -31G/C (rs9904341) is highly associated with overall cancer risk in allelic (C vs. G, OR=1.25,95% CI= 1.15 to 1.37, P<0.00001), homozygous co-dominant (CC vs. GG, OR=1.53, 95% CI= 1.23 to 1.90, P=0.0001), heterozygous co-dominant (CC vs. CG, OR= 1.34, 95% CI= 1.18 to 1.52, P<0.00001), dominant model(CC+CG vs. GG, OR= 1.29, 95% CI= 1.14 to 1.46, P= <0.0001) and recessive model (CG+GG vs. CC, OR= 0.70, 95% CI= 0.61 to 0.81, P<0.00001). The stratified analysis revealed that the variant significantly increases the risk in the Asian population.
conclusion-31G/C (rs9904341) polymorphism of the BIRC5 gene is associated with the risk of cancer in the Asian population. However, further large-scale clinical studies are required to re-evaluate this result in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.